The $2 Trillion Valuation Debate Skips What Anthropic Knows 
Pharmacore secures funding to improve medication regimen reviews in long-term care Income Research + Management Hires Chief Strategy Officer
Erinn King joins the Boston-based fixed income manager to drive the firm’s growth strategy and…
Duff & Phelps Names Nicholas Holmes Co-Portfolio Manager of Water Strategy
Nicholas Holmes appointed portfolio manager and senior analyst CHICAGO–(BUSINESS WIRE)–Duff & Phelps Investment Management Co.,…
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of…
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of…
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types…
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types…
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after…
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after…
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations…
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations…
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with…
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with…
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target…
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target…
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic…
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic…
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage…
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage…
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events…
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events…